Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Marinus Pharma CS
(NQ:
MRNS
)
1.470
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, May 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Marinus Pharma CS
< Previous
1
2
3
4
5
6
7
8
Next >
Marinus Pharmaceuticals Announces FDA Approval of ZTALMY® (ganaxolone) for CDKL5 Deficiency Disorder
March 18, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
Preview: Marinus Pharmaceuticals's Earnings
March 18, 2022
Marinus Pharmaceuticals (NASDAQ:MRNS) is set to give its latest quarterly earnings report on Monday, 2022-03-21. Here's what investors need to know before the announcement....
Via
Benzinga
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
March 15, 2022
From
Marinus Pharmaceuticals, Inc.
Via
Business Wire
Stocks That Hit 52-Week Lows On Wednesday
March 02, 2022
Wednesday's session saw 107 companies set new 52-week lows. Points of Interest From Today's 52-Week Lows: Citigroup (NYSE:C) was the largest company by...
Via
Benzinga
Attention Biotech Investors: Mark Your Calendar For March PDUFA Dates
March 02, 2022
The Food and Drug Administration approval calendar was light in February. Nevertheless, the month saw regulatory nods accorded to some breakthrough therapies. Agios...
Via
Benzinga
Stocks That Hit 52-Week Lows On Monday
February 28, 2022
On Monday morning, 66 companies achieved new lows for the year. Noteable 52-Week Lows: Gilead Sciences (NASDAQ:GILD) was the largest firm on a market cap basis to set a...
Via
Benzinga
Stocks That Hit 52-Week Lows On Friday
February 25, 2022
During Friday's trading, 54 companies set new 52-week lows. Things to Consider About Today's 52-Week Lows: The largest company by market cap to hit a new 52-week...
Via
Benzinga
40 Stocks Moving In Wednesday's Mid-Day Session
February 23, 2022
Gainers Tenneco Inc. (NYSE: TEN) shares jumped 94.1% to $19.38 after the company announced it will be acquired by Apollo Funds. Tenneco also reported a Q4 loss of $0.11 per share...
Via
Benzinga
63 Biggest Movers From Yesterday
February 24, 2022
Gainers Tenneco Inc. (NYSE: TEN) shares surged 93.9% to close at $19.35 on Wednesday after the company announced it will be acquired by Apollo Funds. Tenneco also reported a...
Via
Benzinga
Nervous Markets Rebound As Ukraine Tensions Fade
February 23, 2022
U.S. President Joe Biden said Russia had started to invade Ukraine and announced steps targeting Russia’s sale of sovereign debt abroad, its elites and a pair of banks.
Via
Talk Markets
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
February 23, 2022
Gainers Revelation Biosciences (NASDAQ:REVB) stock increased by 29.9% to $2.0 during Wednesday's pre-market session. The market value of their outstanding shares is at...
Via
Benzinga
The Daily Biotech Pulse: Kodiak Sinks On Adverse Study Outcome, Marinus Flags Delay In Clinical Trial, Mainz Biomed Gains On Positive Regulatory Development
February 23, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Kodiak's Wet AMD Treatment KSI-301 Did Not Meet Primary Endpoint In Phase...
Via
Benzinga
Marinus Pharma Delays Status Epilepticus, IV Ganaxolone Clinical Trials Into 2023
February 23, 2022
Marinus Pharmaceuticals Inc (NASDAQ: MRNS) expects data from the RAISE Phase 3 trial of ganaxolone in refractory status epilepticus in 2H of 2023. Earlier data from the trial...
Via
Benzinga
23 Stocks Moving in Wednesday's Pre-Market Session
February 23, 2022
Gainers Revelation Biosciences, Inc. (NASDAQ: REVB) rose 64.9% to $2.54 in pre-market trading after gaining around 5% on Tuesday. Roth Capital recently initiated coverage on the...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
February 22, 2022
Gainers Revelation Biosciences (NASDAQ:REVB
Via
Benzinga
Marinus Pharmaceuticals Announces Delay to RAISE Phase 3 Clinical Trial in Status Epilepticus and Associated IV Ganaxolone Clinical Trials
February 22, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals to Provide Business Update and Announce Preliminary Fourth Quarter 2021 Financial Results on March 21, 2022
February 16, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
February 10, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Completes In Vivo M2 Metabolite Study and Provides European Regulatory Update
February 03, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
Canadian Biotech Disruptor Lexston Life Sciences is unlocking the God Molecule (LEXTF, ICPT, AKBA, QURE, BNTX, SAVA)
January 19, 2022
Via
AB Newswire
Topics
Bonds
Stocks
Exposures
Debt Markets
US Equities
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
January 14, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference and H.C. Wainwright Bioconnect Conference
January 05, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
December 27, 2021
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Announces New Clinical and Research Data to be Presented at American Epilepsy Society Meeting
December 03, 2021
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Announces Nine Presentations and Virtual Investor Event at American Epilepsy Society 2021 Annual Meeting
November 22, 2021
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals to Present at Multiple Upcoming Investor Conferences
November 15, 2021
From
Marinus Pharmaceuticals
Via
Business Wire
Recap: Marinus Pharmaceuticals Q3 Earnings
November 09, 2021
Marinus Pharmaceuticals (NASDAQ:MRNS) reported its Q3 earnings results on Tuesday, November 9, 2021 at 08:00 AM. Here's what investors need to know about the...
Via
Benzinga
Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2021 Financial Results
November 09, 2021
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 08, 2021
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals to Provide Business Update and Announce Third Quarter 2021 Financial Results on November 9, 2021
October 26, 2021
From
Marinus Pharmaceuticals
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.